Heron Therapeutics Statistics
Share Statistics
Heron Therapeutics has 152.09M shares outstanding. The number of shares has increased by 1.17% in one year.
| Shares Outstanding | 152.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 151.02M |
| Failed to Deliver (FTD) Shares | 267 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 29.98M, so 19.71% of the outstanding shares have been sold short.
| Short Interest | 29.98M |
| Short % of Shares Out | 19.71% |
| Short % of Float | 19.86% |
| Short Ratio (days to cover) | 5.27 |
Valuation Ratios
The PE ratio is -2.12 and the forward PE ratio is null.
| PE Ratio | -2.12 |
| Forward PE | null |
| PS Ratio | 1.85 |
| Forward PS | 1.2 |
| PB Ratio | -6.91 |
| P/FCF Ratio | -3.89 |
| PEG Ratio | n/a |
Enterprise Valuation
Heron Therapeutics Inc. has an Enterprise Value (EV) of 385.78M.
| EV / Earnings | -3.49 |
| EV / Sales | 3.04 |
| EV / EBITDA | -3.72 |
| EV / EBIT | -3.49 |
| EV / FCF | -6.39 |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of -5.11.
| Current Ratio | 2.37 |
| Quick Ratio | 1.84 |
| Debt / Equity | -5.11 |
| Total Debt / Capitalization | 124.3 |
| Cash Flow / Debt | -0.34 |
| Interest Coverage | -28.6 |
Financial Efficiency
Return on equity (ROE) is 3.25% and return on capital (ROIC) is -75.94%.
| Return on Equity (ROE) | 3.25% |
| Return on Assets (ROA) | -0.5% |
| Return on Capital (ROIC) | -75.94% |
| Revenue Per Employee | 1.01M |
| Profits Per Employee | -877.45K |
| Employee Count | 126 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.55 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -33.18% in the last 52 weeks. The beta is 1.81, so Heron Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.81 |
| 52-Week Price Change | -33.18% |
| 50-Day Moving Average | 1.51 |
| 200-Day Moving Average | 2.33 |
| Relative Strength Index (RSI) | 43.79 |
| Average Volume (20 Days) | 3.20M |
Income Statement
In the last 12 months, Heron Therapeutics had revenue of 127.04M and earned -110.56M in profits. Earnings per share was -0.8.
| Revenue | 127.04M |
| Gross Profit | 61.94M |
| Operating Income | -110.61M |
| Net Income | -110.56M |
| EBITDA | -103.79M |
| EBIT | -110.61M |
| Earnings Per Share (EPS) | -0.8 |
Balance Sheet
The company has 28.68M in cash and 179.63M in debt, giving a net cash position of -150.95M.
| Cash & Cash Equivalents | 28.68M |
| Total Debt | 179.63M |
| Net Cash | -150.95M |
| Retained Earnings | -1.91B |
| Total Assets | 220.78M |
| Working Capital | 109.64M |
Cash Flow
In the last 12 months, operating cash flow was -58.79M and capital expenditures -1.54M, giving a free cash flow of -60.33M.
| Operating Cash Flow | -58.79M |
| Capital Expenditures | -1.54M |
| Free Cash Flow | -60.33M |
| FCF Per Share | -0.44 |
Margins
Gross margin is 48.75%, with operating and profit margins of -87.07% and -87.02%.
| Gross Margin | 48.75% |
| Operating Margin | -87.07% |
| Pretax Margin | -87.02% |
| Profit Margin | -87.02% |
| EBITDA Margin | -81.7% |
| EBIT Margin | -87.07% |
| FCF Margin | -47.49% |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -54.42% |
| FCF Yield | -27.08% |
Analyst Forecast
The average price target for HRTX is $6, which is 308.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 308.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jan 13, 2014. It was a backward split with a ratio of 1:20.
| Last Split Date | Jan 13, 2014 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -10.67 |
| Piotroski F-Score | 3 |